[1] Kennedy PGE, Mogensen TH. Varicella-zoster virus infection of neurons derived from neural stem cells. Viruses 2021;13(3):485. https://doi.org/10.3390/v13030485.
[2] Expert Group on the Preparation of Consensus on the Diagnosis and Treatment of Postherpetic Neuralgia. Chinese expert consensus on the diagnosis and treatment of postherpetic neuralgia. Chin J Pain Med 2016;22(3):161-7. http://dx.doi.org/10.3969/j.issn.1006-9852.2016.03.001. (In Chinese).
[3] Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open 2014;4(6):e004833. https://doi.org/10.1136/bmjopen-2014-004833.
[4] Li Y, An ZJ, Yin DP, Liu YM, Huang ZY, Xu JF, et al. Disease burden due to herpes zoster among population aged ≥50 years old in China: a community based retrospective survey. PLoS One 2016;11(4):e0152660. https://doi.org/10.1371/journal.pone.0152660.
[5] Sun XH, Wei Z, Lin HB, Jit M, Li ZW, Fu CX. Incidence and disease burden of herpes zoster in the population aged ≥50 years in China: data from an integrated health care network. J Infect 2021;82(2):253 − 60. https://doi.org/10.1016/j.jinf.2020.12.013.
[6] Ministry of Health of China, State Food and Drug Administration of China. National guideline for the surveillance of adverse events following immunization (AEFI). 2010. http://www.nhc.gov.cn/jkj/wslgf/201402/5dd5633d93174a7c8e93d8af7579a613.shtml. [2024-3-10]. (In Chinese).
[7] Zhang LN, Li Y, Li KL, Li Y, Fan CX, Ren MR, et al. Surveillance of adverse events following immunization in China, 2021-2022. Chin J Vaccines Immun 2024;30(4):470 − 84. https://doi.org/10.19914/j.cjvi.2024079.
[8] Zhang LN, Li KL, Li Y, Fan CX, Li Y, Ren MR, et al. Surveillance of adverse events following immunization in China, 2020. Chin J Vaccines Immun 2022;28(2):208 − 18. https://doi.org/10.19914/j.cjvi.2022041.
[9] Stassijns J, Bollaerts K, Baay M, Verstraeten T. A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among children. Vaccine 2016;34(6):714 − 22. https://doi.org/10.1016/j.vaccine.2015.12.024.
[10] Hesse EM, Shimabukuro TT, Su JR, Hibbs BF, Dooling KL, Goud R, et al. Postlicensure safety surveillance of recombinant zoster vaccine (Shingrix) - United States, October 2017–June 2018. MMWR Morb Mortal Wkly Rep 2019;68(4):91 − 4. https://doi.org/10.15585/mmwr.mm6804a4.
[11] Tavares-Da-Silva F, Co MM, Dessart C, Hervé C, López-Fauqued M, Mahaux O, et al. Review of the initial post-marketing safety surveillance for the recombinant zoster vaccine. Vaccine 2020;38(18):3489 − 500. https://doi.org/10.1016/j.vaccine.2019.11.058.
[12] Colindres R, Wascotte V, Brecx A, Clarke C, Hervé C, Kim JH, et al. Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials. Hum Vaccin Immunother 2020;16(11):2628 − 33. https://doi.org/10.1080/21645515.2020.1741312.
[13] López-Fauqued M, Campora L, Delannois F, El Idrissi M, Oostvogels L, De Looze FJ, et al. Safety profile of the adjuvanted recombinant zoster vaccine: pooled analysis of two large randomised phase 3 trials. Vaccine 2019;37(18):2482 − 93. https://doi.org/10.1016/j.vaccine.2019.03.043.
[14] Goud R, Lufkin B, Duffy J, Whitaker B, Wong HL, Liao JM, et al. Risk of Guillain-Barré syndrome following recombinant zoster vaccine in medicare beneficiaries. JAMA Intern Med 2021;181(12):1623 − 30. https://doi.org/10.1001/jamainternmed.2021.6227.
[15] Nelson JC, Ulloa-Pérez E, Yu O, Cook AJ, Jackson ML, Belongia EA, et al. Active postlicensure safety surveillance for recombinant zoster vaccine using electronic health record data. Am J Epidemiol 2023;192(2):205 − 16. https://doi.org/10.1093/aje/kwac170.